Printer Friendly
The Free Library
14,679,167 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Chiron receives New York State permit to test HIV viral load through reference testing laboratory; service now available nationwide.


EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 8, 1995--Chiron Corp. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:CHIR CHIR Chiricahua National Monument (US National Park Service) ) announced today that the Chiron Reference Testing Laboratory now is accepting HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States.  specimens for viral load testing from physicians in all 50 states.

Most recently, Chiron obtained a permit to test specimens from the state of New York. The Chiron Reference Testing Laboratory was established in July 1994 to provide access to branched DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
 (bDNA) technology for the quantification of HIV RNA (viral load) in patients infected with HIV, the virus that causes AIDS.

The amount of virus present in the blood of HIV patients has been reported to be highly predictive of disease progression. A recent study published in the "Annals of Internal Medicine Annals of Internal Medicine (Ann Intern Med) is an academic medical journal published by the American College of Physicians (ACP). It publishes research articles and reviews in the area of internal medicine. Its current editor is Harold C. Sox. " by Dr. John Mellors from the University of Pittsburgh showed that patients with high levels of HIV RNA in their blood had a much greater likelihood of progressing to AIDS than patients with lower levels.

This finding, coupled with recent advances in the understanding of the role of the virus in infected patients, has led many clinicians and scientists to begin using viral load measurements to individualize patient therapy and evaluate the effectiveness of new treatments for HIV.

HIV viral load HIV viral load AIDS A measure of the amount of HIV RNA in blood, expressed as number of copies/mL of plasma. See AIDS, HIV.  testing by bDNA is performed at the Chiron Reference Testing Laboratory in Emeryville. This service is made available to physicians through Corning Nichols Institute and Corning Clinical Laboratories by calling 800/553-5443 or SmithKline Beecham Clinical Laboratories at 800/877-7003.

CONTACT: Chiron Corp., Emeryville

Larry Kurtz, 510/601-2476

Kimberly Kraemer, 510/601-2412
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 8, 1995
Words:248
Previous Article:FDA Clears Diagnostic Test for Screening more than 25 Rare Diseases in Newborns; First Diagnostic Product from Glyko Biomedical Features its Patented...
Next Article:Motorola EMBARC Introduces The Know-It-All, An Innovative Wireless Information Sign; New wireless sign provides information and entertainment...
Topics:



Related Articles
New tests mark big leap in HIV diagnosis. (three-drug combination appears to eradicate HIV in the blood)(Brief Article)
Vaccine Advance: Monkeys Still Infected, But Protected from Illness.
HIV Testing 101 (Part 2 of 2).
HIV Resistance: Data and spin.(overview on drug-resistant HIV infection)
BODY : FITNESS & EXERCISE VIRAL LOAD VALUABLE BAROMETER IN AIDS CASES.(L.A. LIFE)
BAYER TO ACQUIRE VISIBLE GENETICS FOR $61.4 MILLION IN CASH.
"Shy" study suggests new treatment mechanism.
New testing for very early HIV diagnosis.
ADVAX, new DNA vaccine in human trial; HIV-negative volunteers needed in New York City or Rochester, NY areas.
HIV-1 genetic diversity in antenatal cohort, Canada.(RESEARCH)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles